Monday, April 27, 2020

Evofem Biosciences Gains $25M In Convertible Note

San Diego-based biopharmaceuticals developer Evofem Biosciences, a publicly held developer of biopharmaceuticals aimed at contraception, says it has received $25M in a convertible note financing. The company says it has received $15M of that amount, with remaining $10M to be funded at its investor's discretion. Source of the funding was not announced. The

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.